Recommendation 117: We suggest that metformin may be considered a first-line agent for type 2 diabetes treatment (Weak Recommendation, Moderate Quality Evidence).
Values and preferences: Metformin is the current Diabetes Canada first line treatment for type 2 diabetes.
Recommendation 118: We recommend that thiazolidinediones should not be used in patients with HF (Strong Recommendation, High Quality Evidence).
Values and preferences: Both pioglitazone and rosiglitazone have been shown in studies to increase the risk for heart failure.